INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• INmune Bio, Inc. has received a consensus recommendation of "Moderate Buy" from seven research firms, with one sell rating and three buy ratings.
• The average twelve-month target price for INmune Bio among analysts is $18.40, while the stock opened at $2.01.
• Significant institutional investments have been noted, with JPMorgan Chase & Co. increasing its stake by 1,042.7% in the second quarter.

Shares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.40.

A number of analysts recently issued reports on INMB shares. Raymond James Financial downgraded shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a report on Monday, June 30th. Scotiabank restated a "sector underperform" rating on shares of INmune Bio in a research note on Tuesday, July 1st. Wall Street Zen downgraded INmune Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 2nd. BTIG Research reissued a "neutral" rating on shares of INmune Bio in a report on Tuesday, July 1st. Finally, Maxim Group decreased their target price on INmune Bio from $30.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, July 2nd.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd raised its position in shares of INmune Bio by 240.9% in the second quarter. XTX Topco Ltd now owns 125,847 shares of the company's stock valued at $291,000 after purchasing an additional 88,928 shares during the period. Millennium Management LLC boosted its holdings in INmune Bio by 43.9% in the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after buying an additional 88,823 shares during the period. JPMorgan Chase & Co. grew its stake in INmune Bio by 1,042.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company's stock valued at $169,000 after buying an additional 66,700 shares in the last quarter. Two Sigma Investments LP raised its holdings in INmune Bio by 444.8% during the 4th quarter. Two Sigma Investments LP now owns 66,384 shares of the company's stock valued at $310,000 after acquiring an additional 54,200 shares during the period. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of INmune Bio during the second quarter worth $87,000. Institutional investors own 12.72% of the company's stock.

INmune Bio Stock Performance

Shares of INMB stock opened at $2.01 on Friday. The company has a market capitalization of $53.44 million, a price-to-earnings ratio of -0.81 and a beta of 1.03. INmune Bio has a 52-week low of $1.71 and a 52-week high of $11.64. The company has a 50-day simple moving average of $2.35 and a two-hundred day simple moving average of $5.57.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, sell-side analysts forecast that INmune Bio will post -2.24 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.